210 related articles for article (PubMed ID: 28784867)
1. Trends in Neoadjuvant Approaches in Pancreatic Cancer.
Du L; Wang-Gillam A
J Natl Compr Canc Netw; 2017 Aug; 15(8):1070-1077. PubMed ID: 28784867
[TBL] [Abstract][Full Text] [Related]
2. The role of neoadjuvant therapy in pancreatic cancer: a review.
Russo S; Ammori J; Eads J; Dorth J
Future Oncol; 2016 Mar; 12(5):669-85. PubMed ID: 26880384
[TBL] [Abstract][Full Text] [Related]
3. Updates on the use of neoadjuvant therapy in borderline resectable pancreatic cancer.
Chandhok NS; Saif MW
JOP; 2014 Mar; 15(2):91-4. PubMed ID: 24618425
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer.
Nurmi A; Mustonen H; Parviainen H; Peltola K; Haglund C; Seppänen H
Acta Oncol; 2018 Jun; 57(6):799-806. PubMed ID: 29241394
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits.
Heinrich S; Lang H
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28933761
[TBL] [Abstract][Full Text] [Related]
6. The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings.
Badiyan SN; Molitoris JK; Chuong MD; Regine WF; Kaiser A
Surg Oncol Clin N Am; 2017 Jul; 26(3):431-453. PubMed ID: 28576181
[TBL] [Abstract][Full Text] [Related]
7. Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy.
di Sebastiano P; Grottola T; di Mola FF
Updates Surg; 2016 Sep; 68(3):235-239. PubMed ID: 27629483
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma.
Abbott DE; Tzeng CW; Merkow RP; Cantor SB; Chang GJ; Katz MH; Bentrem DJ; Bilimoria KY; Crane CH; Varadhachary GR; Abbruzzese JL; Wolff RA; Lee JE; Evans DB; Fleming JB
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S500-8. PubMed ID: 23397153
[TBL] [Abstract][Full Text] [Related]
9. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.
Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S
Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840
[TBL] [Abstract][Full Text] [Related]
10. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.
Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ
J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis.
de Geus SW; Eskander MF; Bliss LA; Kasumova GG; Ng SC; Callery MP; Tseng JF
Surgery; 2017 Mar; 161(3):592-601. PubMed ID: 28341441
[TBL] [Abstract][Full Text] [Related]
12. Status of neoadjuvant therapy for resectable pancreatic cancer.
Hoffman JP
Surg Oncol Clin N Am; 2010 Apr; 19(2):411-8. PubMed ID: 20159522
[TBL] [Abstract][Full Text] [Related]
13. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant vs adjuvant therapy for resectable pancreatic cancer: the evolving role of radiation.
Hoffe S; Rao N; Shridhar R
Semin Radiat Oncol; 2014 Apr; 24(2):113-25. PubMed ID: 24635868
[TBL] [Abstract][Full Text] [Related]
15. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
[TBL] [Abstract][Full Text] [Related]
16. Analysis of radiotherapy impact on survival in resected stage I/II pancreatic cancer patients: a population-based study.
Han D; Gao F; Liu JL; Wang H; Fu Q; Yang GW
BMC Cancer; 2021 May; 21(1):560. PubMed ID: 34001035
[TBL] [Abstract][Full Text] [Related]
17. [Neoadjuvant therapy vs. upfront resection for resectable pancreatic cancer].
Strobel O; Büchler MW
Chirurg; 2017 Jul; 88(7):619. PubMed ID: 28573533
[No Abstract] [Full Text] [Related]
18. A Qualitative Review of Neoadjuvant Chemotherapy in Resectable Pancreatic Adenocarcinoma.
Blair AB; Sorber R; Rozich NS; Burkhart RA
Pancreas; 2019 Sep; 48(8):973-984. PubMed ID: 31425483
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant therapy for resectable pancreatic cancer.
Raut CP; Evans DB; Crane CH; Pisters PW; Wolff RA
Surg Oncol Clin N Am; 2004 Oct; 13(4):639-61, ix. PubMed ID: 15350939
[TBL] [Abstract][Full Text] [Related]
20. Multimodal treatment of resectable pancreatic ductal adenocarcinoma.
Silvestris N; Brunetti O; Vasile E; Cellini F; Cataldo I; Pusceddu V; Cattaneo M; Partelli S; Scartozzi M; Aprile G; Casadei Gardini A; Morganti AG; Valentini V; Scarpa A; Falconi M; Calabrese A; Lorusso V; Reni M; Cascinu S
Crit Rev Oncol Hematol; 2017 Mar; 111():152-165. PubMed ID: 28259290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]